cover
Contact Name
Abd. Kakhar Umar
Contact Email
abdulkaharumar@gmail.com
Phone
+6282216335184
Journal Mail Official
sciphar@etflin.com
Editorial Address
Sungai Manonda Street, Syukur Aisle No. 2, RT 004/ RW 001, Duyu Village, Tatanga District
Location
Kota palu,
Sulawesi tengah
INDONESIA
Sciences of Pharmacy
Published by ETFLIN
ISSN : 28307046     EISSN : 28307259     DOI : https://doi.org/10.58920/sciphar
Sciences of Pharmacy (SciPhar) is an international, peer-reviewed open-access journal of pharmacy. We offer a platform and place for researchers and intellectuals, especially the youth, to share their insights and works. Every year, we hold seminars/webinars under the ETFLIN Scientific Society to facilitate the exchange of information concerning pharmacist research progress. Publication on SciPhar is free of charge at any stage. Scope We are accepting articles related to drug development (preclinical and clinical drug development, drug delivery, and pharmaceutical formulation). Fundamental and clinical pharmacology (drug mechanisms, pharmacokinetics, pharmacodynamics, drug metabolism, and pharmacogenetics). Pharmaceuticals (gene-based, cell-based, protein-based therapy, other drug modalities, routes of administration, drug classes, drug nomenclature). Drug toxicity and safety (drug-drug interactions, adverse drug reactions, mechanisms of drug toxicity, pharmacovigilance). Pharmacoepidemiology, pharmacoeconomics, and pharmacy.
Articles 112 Documents
Evaluation of Quality of Life in Breast Cancer Patients: A Cross-Sectional Comparative Study between Targeted Therapy and Conventional Chemotherapy Pratama, Kharisma Jayak; Luthfiyanti, Niken
Sciences of Pharmacy Volume 4 Issue 4
Publisher : ETFLIN Publishing House

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58920/sciphar0404453

Abstract

Breast cancer is one of the most common cancers worldwide, with treatment often involving conventional therapies such as chemotherapy. Although effective, chemotherapy is often accompanied by significant side effects and reduces patients' quality of life. Targeted therapy, which targets specific molecular mechanisms in cancer cells, offers the potential to address these issues with higher efficacy and fewer side effects. This study aims to compare the quality of life of breast cancer patients receiving targeted therapy with chemotherapy. The study design used a comparative cross-sectional design involving 60 patients (30 receiving targeted therapy, 30 receiving chemotherapy) selected via consecutive sampling at RSUD Moewardi in Surakarta (January–June 2025). Data were collected using the validated Indonesian version of the EORTC QLQ-C30 questionnaire. Statistical analysis included parametric t-tests and non-parametric Mann-Whitney U tests. The study results showed that the targeted therapy group had better role functioning (p = 0.047.95% CI=0.044-0.053) and significantly lower pain (p= 0.001.95% CI=0.000-0.002) and nausea (p = 0.019.95% CI=0.016-0.021) symptoms compared to chemotherapy. Global health status did not differ significantly (p= 0.545.95% CI=0.536-0.556). Age (p = 0.012.95% CI=0.08-0.012) and stadium (p = 0.001.95% CI=0.001-0.003) significantly influenced global QoL. Targeted therapy provided advantages in functional aspects and specific symptoms, although not in global QoL. A key study limitation is its cross-sectional design, which prevents the establishment of causal relationships between the type of therapy and quality of life outcomes.
Analysis of Antibiotic Therapy Accuracy and Drug Interaction in Pneumonia Inpatients at The Islamic Hospital Jakarta Cempaka Putih Khairani, Sondang; Manninda, Reise; Ariani, Lusiana; Iskandar, Benni; Hidayati, Nabila Nur
Sciences of Pharmacy Volume 4 Issue 4
Publisher : ETFLIN Publishing House

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58920/sciphar0404456

Abstract

Polypharmacy may increase the risk of drug interactions affecting toxicity and therapeutic efficacy in pneumonia patients. This study aimed to analyse evaluation of pneumonia management, polypharmacy, relationship between polypharmacy and occurrence of drug-drug interactions, and relationship between drug-drug interactions and length of hospital stay of pneumonia patients. The study design used a quantitative descriptive approach with cross-sectional and retrospective data collection and a total sample of 113 samples that met the criteria. Analyses were performed using Spearman's rho correlation test to assess the association of polypharmacy with drug interactions, and the association of drug interactions with length of hospital stay. Medication accuracy was measured using PDPI (The Indonesian Lung Doctors Assosiaciation) guidelines, drug interactions using drugs.com and/or Medscape.com. Results showed 59.29% of patients were female, with the majority aged over 65 (55.65%). Most patients (91.15%) paid with BPJS, 62.61% were hospitalised for 1-5 days and 81.74% had comorbidities. Treatment accuracy in this study was 49.56%. 106 drug interactions were identified in a total of 226 cases. 66% of the interactions were pharmacodynamic with moderate severity (79%), such as the interaction between combivent and ondansetron. Mild pharmacokinetic interactions were common, especially between ranitidine and paracetamol (22 cases). There is a correlation between polypharmacy and drug interactions with a p-value 0.000 and there is a correlation between the number of drug interactions and length of hospitalisation with p-value 0.000. Conclusion of this study is polypharmacy increases the risk of drug interactions and affects the length of hospital stay in pneumonia patients.

Page 12 of 12 | Total Record : 112